Janssen Collaborates with Emergent BioSolutions to Accelerate the Manufacturing of its Vaccine Against COVID-19

 Janssen Collaborates with Emergent BioSolutions to Accelerate the Manufacturing of its Vaccine Against COVID-19

Shots:

  • Janssen partnered with Emergent to develop more than a billion doses of a COVID-19 vaccine candidate, as it anticipates scaling up global manufacturing of its potential treatment. The agreement valued ~135M
  • Emergent will provide manufacturing services with its molecule-to-market CDMO offering, beginning in 2020 and will reserve operations capacity to support manufacturing of J&J’s COVID-19 vaccine candidate leveraging Janssen’s AdVac and PER.C6 technologies initiating in 2021
  • J&J has initiated preparations for clinical vaccine production at its facility in the Netherlands, intending to commence P-I clinical studies of its vaccine candidate in Sept’2020

Click here ­to­ read full press release/ article | Ref: J&J | Image: Maryland is Open for Business

Related News:  Janssen Expands its Collaboration with BARDA to Expedite the Discovery of COVID-19 Therapies

 

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post